Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Oxford Bioscience Partners

Investor type Micro VC
Founders Cornelius T. Ryan Edmund M. Olivier

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 123
Average round size
info
The average size of a deal this fund participated in
$20M
Portfolio companies 65
Rounds per year 4.10
Lead investments 15
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.47
Exits 40
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Biotechnology
  • Medical Device
  • Pharmaceutical
  • Medical
Summary

Oxford Bioscience Partners appeared to be the VC, which was created in 1992. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Boston.

Besides them, we counted 1 critical employee of this fund in our database.

The fund has exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Life Science, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Sirna Therapeutics, Catalyst Biosciences, Mitralign. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Oxford Bioscience Partners, startups are often financed by HealthCare Ventures, Giza Venture Capital, ARCH Venture Partners. The meaningful sponsors for the fund in investment in the same round are MPM Capital, Medica Venture Partners, HLM Venture Partners. In the next rounds fund is usually obtained by Triathlon Medical Venture Partners, HLM Venture Partners, ARCH Venture Partners.

The higher amount of exits for fund were in 2006. The fund is constantly included in 2-6 deals per year. Speaking about the real fund results, this VC is 2 percentage points less often commits exit comparing to other organizations. When the investment is from Oxford Bioscience Partners the average startup value is 10-50 millions dollars. This Oxford Bioscience Partners works on 5 percentage points more the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2007. The common things for fund are deals in the range of 10 - 50 millions dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Oxford Bioscience Partners:
Typical Co-investors
Oxford Bioscience Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Oxford Bioscience Partners:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Ceres

Agriculture
Biotechnology
Farming
Fuel
Renewable Energy
$75M27 Sep 2021 California, United States

Yolia Health

Education
Health Care
$3M01 Jan 2017 San Diego, California, United States

CardioFocus

Biotechnology
Health Care
Medical Device
Pharmaceutical
Surgical Devices
Therapeutic Devices
$2M09 May 2014 Marlborough, Massachusetts, United States

Affinium Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$11M11 Sep 2013 Austin, Texas, United States

Dicerna Pharmaceuticals

Biotechnology
Genetics
Health Care
Pharmaceutical
$60M31 Jul 2013 Massachusetts, United States

Mitralign

Health Care
Medical
Medical Device
$35M16 May 2012 Massachusetts, United States

Glori Energy

Clean Energy
Energy
Oil and Gas
Renewable Energy
$20M24 Jan 2012 Houston, Texas, United States

CardioFocus

Biotechnology
Health Care
Medical Device
Pharmaceutical
Surgical Devices
Therapeutic Devices
$30M28 Feb 2011 Marlborough, Massachusetts, United States

SuperDimension

Health Care
Medical
Medical Device
$9M07 Sep 2010 Minneapolis, Minnesota, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Oxford Bioscience Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: